Please note that some translations using Google Translate may not be accurately represented and downloaded documents cannot be translated. Dana-Farber assumes no liability for inaccuracies that may result from using this third-party tool, which is for website translation and not clinical interactions. You may request a live medical interpreter for a discussion about your care.
Read about advances in hematologic malignancies in our biannual eNewsletter for clinicians nationwide in the field of hematologic oncology.
A 69-year-old man with a long-standing history of mild normocytic anemia and thrombocytopenia presented to his hematologist in Rhode Island for a routine follow-up visit and was noted to have new severe pancytopenia.
The myeloid malignancies, including acute myeloid leukemia (AML), myelodysplastic syndromes (MDS), and myeloproliferative neoplasms (MPN) are a spectrum of biologically related, but clinically heterogeneous diseases.
Blinatumomab is a bispecific CD19-directed CD3 T-cell engager monoclonal antibody that was approved by the Food and Drug Administration (FDA) for treatment of patients with relapsed/refractory acute lymphoblastic leukemia (B-ALL) in December 2014
The DNA methytransferase inhibitors azacitidine (Vidaza) and decitabine (Dacogen) are both FDA-approved for treatment of all French-American-British (FAB) Co-operative Group subtypes of myelodysplastic syndromes (MDS), and these drugs can alter the natural history of the disease.
If you are a clinician specializing in the field of hematologic oncology, we can help you refer a patient, explore open clinical trials, learn about CME events, and more.
View our full list of hematologic malignancies resources for referring providers.